The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)

Launched by RUIJIN HOSPITAL · Sep 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two types of imaging tests, called 18F-FDG and 68Ga-FAPI PET/CT scans, to see how well they can help doctors understand advanced colorectal cancer, especially when it has spread to the lining of the abdomen (known as peritoneal metastasis) and possibly other areas of the body. The main goal is to determine how effective these scans are in evaluating treatment outcomes and predicting how well patients might do with their cancer.

To be eligible for this study, participants must have been diagnosed with colorectal cancer and have signs suggesting it has spread to the abdomen or other places. They need to be at least 18 years old, have a life expectancy of at least three months, and be in good health overall. Participants will need to agree to follow the study's guidelines and attend follow-up appointments. It's important to note that pregnant or breastfeeding women, as well as those with certain health conditions, cannot join the study. If you or someone you know is interested, it could be a valuable opportunity to help advance our understanding of colorectal cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases.
• • 2. Patients voluntarily enrolled in this study by signing an informed consent form
• • 3. Age ≥ 18 years
• • 4. Expected life expectancy ≥ 3 months
• • 5. Adequate organ and bone marrow function
• • 6. Willingness to adhere to the study protocol and follow-up programme
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding women.
• • 2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
• • 3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
• • 4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis